Viking Therapeutics: M&A Speculation Intensifies Amid Clinical Momentum

The shares of Viking Therapeutics have delivered a remarkable 34% gain over the past three months, signaling a powerful resurgence. This impressive rally coincides with significant clinical progress in the competitive obesity drug market, fueling intense speculation. With the recent seismic shift in the industry following a major acquisition, investors are questioning whether Viking is positioning itself for a multi-billion dollar exit or if its growth narrative is already fully reflected in its valuation.

Viking Therapeutics finds itself in an increasingly strategic position. The recent Pfizer-Metsera deal, valued at $10 billion and involving a bidding contest with Novo Nordisk, has reignited merger and acquisition fervor across the sector. This environment places independent companies with Read more...